Carmat was co-created by Truffle Capital based on an idea of Professor Alain Carpentier. The development of a total artificial heart is a major technical challenge and this investment, which is emblematic for Truffle Capital, has a multiple of more than x10. This creation perfectly illustrates Truffle Capital's investment strategy of creating and financing technology companies that revolutionize medicine, extend or save lives while generating capital gains.
See website
Synoptical view
- Truffle investment
- € 17M
- Stock
- Carmat is listed on EURONEXT GROWTH PARIS since 2010
Management team
Board of Directors
As a former Paris hospital intern in immunology and hematology, Dr Pouletty holds a doctorate in medicine from the University of Paris VI and a master's degree in immunology and virology from the Institut Pasteur. He was a post-doctoral researcher (1986-1988) at Stanford University.
He is the winner of the 1999 American Liver Foundation Award. Doctor Philippe Pouletty is a Chevalier de la Légion d'Honneur.
">
Philippe Pouletty, M.D.
Co-Founder & CEO at Truffle Capital
In summary
Founded in 2008, designer and developer of the world's most advanced total artificial heart project; Carmat's goal is to fill the well-known heart transplant gap for the tens of thousands of people suffering from irreversible terminal heart failure, the most severely affected population among the 20 million patients with this progressive disease in Europe and the United States. Carmat intends to become the number one leader in heart transplantation.
KEY STEPS
2008
Creation of Carmat by Truffle, Airbus and Alain Carpentier
2010
IPO
2013
1st successful implementation
2016
Beginning of the pivotal study
2018
European Investment Bank loan of €30 million / Jean-Pierre Garnier appointed Chairman of the Board of Directors
2019
Fda approval for a clinical study
2019
Reserved over-subscribed offer of €60 million
News
